The Lancet Oncology in conversation with

Mark Lythgoe on UK oncology drug approval after Brexit

March 27, 2023 The Lancet Oncology
Mark Lythgoe on UK oncology drug approval after Brexit
The Lancet Oncology in conversation with
More Info
The Lancet Oncology in conversation with
Mark Lythgoe on UK oncology drug approval after Brexit
Mar 27, 2023
The Lancet Oncology

Dr Mark Lythgoe (Imperial College London, London, UK), discusses his new Review, "From The European Medicines Agency to Project Orbis: New activities and challenges to facilitate UK Oncology Drug Approval following Brexit".

Tell us what you thought about this episode by sending us a text message

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Show Notes

Dr Mark Lythgoe (Imperial College London, London, UK), discusses his new Review, "From The European Medicines Agency to Project Orbis: New activities and challenges to facilitate UK Oncology Drug Approval following Brexit".

Tell us what you thought about this episode by sending us a text message

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv